BridgeBio Pharma Quarterly Income Statement
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma revenue and earnings
In the quarter ended Jun 30, 2026, BridgeBio Pharma generated $243.7 million in revenue, up 120.4% from the same quarter a year earlier. BridgeBio Pharma reported a net loss of $155.9 million, compared with a loss of $183.8 million a year earlier. Gross margin was 93.8% (down from 96.7%) and operating margin -43.9%.
Diluted earnings per share came in at -$0.78.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 243.68M | 194.51M | 154.18M | 120.70M | 110.56M | 116.63M | 5.88M | 2.73M | 2.17M | 211.12M | 1.75M | 4.09M |
| Revenue growth (YoY) | +120.39% | +66.78% | +2521.18% | +4318.01% | +4999.86% | -44.76% | +237.08% | -33.22% | +32.11% | +11461.88% | -6.68% | +1110.36% |
| Cost of Revenue | 15.05M | 9.94M | 8.11M | 6.56M | 3.65M | 2.64M | 2.08M | 598.00K | 598.00K | 598.00K | 598.00K | 598.00K |
| Gross Profit | 228.63M | 184.58M | 146.07M | 114.14M | 106.91M | 113.99M | 3.80M | 2.13M | 1.57M | 210.52M | 1.15M | 3.49M |
| Operating Expenses | 335.71M | 290.53M | 285.63M | 259.34M | 241.19M | 218.37M | 229.82M | 193.88M | 177.11M | 210.18M | 178.56M | 161.19M |
| Research & Development | 149.45M | 126.64M | 116.42M | 112.87M | 111.23M | 111.43M | 130.35M | 120.44M | 114.69M | 140.97M | 130.23M | 125.14M |
| Selling, General & Admin | 186.26M | 163.90M | 158.09M | 137.62M | 129.15M | 106.36M | 94.78M | 68.82M | 59.52M | 65.81M | 47.58M | 35.78M |
| Operating Income | -107.08M | -105.96M | -139.56M | -145.20M | -134.28M | -104.37M | -226.03M | -191.75M | -175.54M | 343.00K | -177.42M | -157.69M |
| Interest Expense | 13.28M | 12.94M | 11.64M | 11.74M | 11.61M | 18.12M | 21.52M | 23.06M | 22.94M | 23.47M | 20.27M | 20.31M |
| Other Income (Expense) | -48.81M | -60.60M | -55.19M | -41.28M | -47.38M | -65.24M | -40.21M | 27.50M | 100.00M | -36.50M | 7.09M | -21.80M |
| Pretax Income | -155.89M | — | -194.75M | -186.48M | -181.66M | — | -266.24M | -164.25M | -75.54M | — | — | — |
| Income Tax | 0 | — | -120.00K | -1.54M | 2.10M | 0 | 1.15M | 0 | 0 | 0 | 0 | 0 |
| Net Income | -155.89M | -166.56M | -194.63M | -184.94M | -183.76M | -169.61M | -267.39M | -164.25M | -75.54M | -36.16M | -170.33M | -179.49M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 | -1.43 | -0.86 | -0.39 | -0.20 | -0.97 | -1.08 |
| EPS (Diluted) | -0.78 | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 | -1.43 | -0.86 | -0.39 | -0.20 | -0.97 | -1.08 |
| Shares Outstanding (Basic) | 195.79M | 194.79M | — | 191.85M | 190.52M | 190.15M | — | 188.51M | 187.59M | 178.71M | — | 163.31M |
| Shares Outstanding (Diluted) | 195.79M | 194.79M | — | 191.85M | 190.52M | 190.15M | — | 188.51M | 187.59M | 178.71M | — | 163.31M |
| EBITDA | -106.03M | -104.77M | -138.13M | -143.80M | -132.96M | -103.09M | -224.66M | -190.21M | -173.97M | 1.94M | -175.83M | -156.05M |
| Gross Margin | 93.83% | 94.89% | 94.74% | 94.56% | 96.70% | 97.74% | 64.57% | 78.11% | 72.42% | 99.72% | 65.73% | 85.38% |
| Operating Margin | -43.94% | -54.47% | -90.52% | -120.30% | -121.45% | -89.49% | -3842.69% | -7018.67% | -8096.82% | 16.00% | -10167.11% | -3854.61% |
| Net Margin | -63.97% | -85.63% | -126.24% | -153.22% | -166.20% | -145.42% | -4545.89% | -6012.23% | -3484.50% | -17.13% | -9760.92% | -4387.39% |
This table shows 12 quarterly periods of BridgeBio Pharma's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a income statement?